Effect of Probenecid on Synovial Fluid ATP Levels in CPPD

• Status: Completed
• Trial end date: 2021-04-08
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the hypothesis that probenecid, a medication currently used for gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate deposition disease (CPPD), another common type of crystal-related arthritis. There is good evidence that CPPD results from an excess of ATP in joints. The investigators will measure levels of ATP in joint fluid before and after 5 days of treatment with probenecid. This study will serve to rationalize larger studies of probenecid in CPPD.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Office of Research and Development
• Treatments: Probenecid

Criteria

Inclusion Criteria:

Inclusion criteria:

• Age >21 years,

• CPPD diagnosed by Ryan /McCarty criteria

• Joint effusion in a shoulder or knee

Exclusion Criteria:

Exclusion criteria:

• Inability to sign informed consent

• Age <21 years

• History of renal stones

• Significant renal dysfunction (CKD >stage 2)

• Blood dyscrasias

• Current use of drugs which interact with probenecid

• Concurrent gout

• Active infection, including bacteremia and overlying cellulitis

• Recent joint trauma

• Intra-articular corticosteroids in the affected joint within three months